ICU Medical (ICUI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
Annual Meeting scheduled for May 13, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote on key proposals by May 12, 2026.
Voting matters and shareholder proposals
Election of seven directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) is recommended for approval.
Proposal to amend the Certificate of Incorporation to adopt simple majority voting provisions.
Proposal to allow shareholders with 25% ownership to call special meetings, and a separate advisory proposal for a 10% threshold.
Board of directors and corporate governance
Seven director nominees listed for election, including Vivek Jain, David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, and Kolleen T. Kennedy.
Latest events from ICU Medical
- Shareholders will vote on directors, governance reforms, and executive pay, with ESG in focus.ICUI
Proxy filing2 Apr 2026 - Shareholders will vote on directors, auditor, executive pay, and governance reforms, with board-backed ESG focus.ICUI
Proxy filing23 Mar 2026 - Margin expansion, pump upgrades, and software innovation drive growth amid integration progress.ICUI
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Innovation, unified platforms, and margin expansion drive growth and future capital returns.ICUI
47th Annual Raymond James Institutional Investor Conference9 Mar 2026 - 2026 guidance targets $400–$430M adjusted EBITDA and low- to mid-single-digit organic growth.ICUI
Q4 202519 Feb 2026 - Q2 revenue up 8.6%, net loss widens, but full-year earnings guidance is raised.ICUI
Q2 20242 Feb 2026 - Stabilized operations and innovation position the company for growth and margin expansion.ICUI
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Innovation, margin gains, and integration fuel growth and future opportunities in IV therapy.ICUI
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Q3 revenue up 6.5% YoY; IV solutions JV with Otsuka to drive growth and reduce debt.ICUI
Q3 202414 Jan 2026